Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran

International Journal of Drug Policy

Volumn 21, Issue 5, 2010, Pages 422-424

  Farnia, Marziyeh ^a   Ebrahimi, Bahman ^a   Shams, Ali ^a   Zamani, Saman ^b  

^a Iran Prison Organization   (Iran)

^b KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

Author keywords

HIV; Iran; Methadone maintenance treatment; Prison

Indexed keywords

ILLICIT DRUG; METHADONE; OPIATE;

ARTICLE; CLINICAL ASSESSMENT; DRUG DOSE INCREASE; DRUG EFFICACY; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; INFECTION RISK; IRAN; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; OPIATE ADDICTION; PRIORITY JOURNAL; PRISONER; RISK REDUCTION; VIRUS TRANSMISSION;

ALCOHOLISM; ANALGESICS, OPIOID; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; IRAN; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRISONERS; PRISONS; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 77954657787     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2010.03.008     Document Type: Article

References (24)

1. Bayanzadeh S.A., Afshar P. A study of effectiveness of pharmacological and psychological interventions in reducing drug related harms and improving psychological status of drug dependent prisoners 2004, Tehran Psychiatric Institute, Iran Prison Organization, and United Nations Office on Drugs and Crime, Iran, Tehran.
2. Buavirat A., Page-Shafer K., van Griensven G.J., Mandel J.S., Evans J., Chuaratanaphong J., et al. Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: Case-control study. British Medical Journal 2003, 326(7384):308.
3. Dolan K.A., Shearer J., MacDonald M., Mattick R.P., Hall W., Wodak A.D. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug and Alcohol Dependence 2003, 72(1):59-65.
4. Dolan K.A., Shearer J., White B., Zhou J., Kaldor J., Wodak A.D. Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction 2005, 100(6):820-828.
5. Dolan K.A., Wodak A. HIV transmission in a prison system in an Australian State. The Medical Journal of Australia 1999, 171(1):14-17.
6. Eshrati B., Asl R.T., Dell C.A., Afshar P., Millson P.M., Kamali M., et al. Preventing HIV transmission among Iranian prisoners: Initial support for providing education on the benefits of harm reduction practices. Harm Reduction Journal 2008, 5:21.
7. Gossop M., Marsden J., Stewart D., Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: Two-year follow-up results from the National Treatment Outcome Research Study. Drug and Alcohol Dependence 2001, 62(3):255-264.
8. Health and Treatment Headquarter of Iran Prison Organization An overview on HIV/AIDS in prisons of Islamic Republic of Iran 2006, Iran Prison Organization, Tehran.
9. Institute of Medicine Preventing HIV infection among injecting drug users in high risk countries: An assessment of the evidence 2006, National Academic Press, Washington, DC.
10. Kheirandish P., Seyedalinaghi S.A., Hosseini M., Jahani M.R., Shirzad H., Foroughi M., et al. Prevalence and correlates of HIV infection among male injection drug users in detention, Tehran, Iran. Journal of Acquired Immune Deficiency Syndromes 2009.
11. Larney S., Dolan K. A literature review of international implementation of opioid substitution treatment in prisons: Equivalence of care?. European Addiction Research 2009, 15(2):107-112.
12. Macalino G.E., Vlahov D., Sanford-Colby S., Patel S., Sabin K., Salas C., et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. American Journal of Public Health 2004, 94(7):1218-1223.
13. Razzaghi E., Nassirimanesh B., Afshar P., Ohiri K., Claeson M., Power R. HIV/AIDS harm reduction in Iran. Lancet 2006, 368(9534):434-435.
14. Razzaghi E.M., Rahimi M.A. Injection drug use in Tehran 2005, Tehran University of Medical Sciences, Tehran, Iran.
15. Stark K., Bienzle U., Vonk R., Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. International Journal of Epidemiology 1997, 26(6):1359-1366.
16. Taylor A., Goldberg D., Emslie J., Wrench J., Gruer L., Cameron S., et al. Outbreak of HIV infection in a Scottish prison. British Medical Journal 1995, 310(6975):289-292.
17. Tomasino V., Swanson A.J., Nolan J., Shuman H.I. The Key Extended Entry Program (KEEP): A methadone treatment program for opiate-dependent inmates. The Mount Sinai Journal of Medicine 2001, 68(1):14-20.
18. UNAIDS Islamic Republic of Iran country report on monitoring of the United Nations General Assembly special session on HIV and AIDS declaration of commitment 2006, Office of the Under-secretary for Health, Ministry of Health and Medical Education, Centre for Diseases Management.
19. WHO Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence 2009, WHO.
20. WHO/UNODC/UNAIDS Substitution maintenance treatment in the management of opioid dependence and HIV/AIDS prevention: Position paper 2004, World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS., Geneva.
21. WHO/UNODC/UNAIDS Interventions to address HIV in prisons: Drug dependence treatments 2007, World Health Organization, Geneva.
22. Zamani S., Farnia M., Tavakoli S., Gholizadeh M., Nazari M., Seddighi A.A., et al. A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran. International Journal of Drug Policy 2009.
23. Zamani S., Kihara M., Gouya M.M., Vazirian M., Nassirimanesh B., Ono-Kihara M., et al. High prevalence of HIV infection associated with incarceration among community-based injecting drug users in Tehran, Iran. Journal of Acquired Immune Deficiency Syndromes 2006, 42(3):342-346.
24. Zamani S., Kihara M., Gouya M.M., Vazirian M., Ono-Kihara M., Razzaghi E.M., et al. Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. AIDS 2005, 19(7):709-716.